Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

BACKGROUND: Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials. We report results from the PERSIST study, which was designed to assess the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Bo, Li, Gang, Li, Xiaohong, Wu, Shan, Yu, Tingmin, Li, Xiang, Zhao, Hongru, Jia, Zhihua, Zhuang, Junpeng, Yu, Shengyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330971/
https://www.ncbi.nlm.nih.gov/pubmed/35896988
http://dx.doi.org/10.1186/s10194-022-01458-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330971/
https://www.ncbi.nlm.nih.gov/pubmed/35896988
http://dx.doi.org/10.1186/s10194-022-01458-0

Ejemplares similares